Hoyoung Huh, 41, U.S. citizen, is Chairman of the Boards of BiPar Sciences Inc., Geron Corp. (NASDAQ: GERN), and Epizyme Inc. He is a global leader in the biotechnology and healthcare arena, being9 involved in formation and growth of innovative organizations across the U.S., Europe and Asia. Dr. Huh was BiPar's President and CEO, where he led the merger of BiPar with the French pharmaceutical firm Sanofi-Aventis (EURONEXT: SAN and NYSE: SNY) in 2009. BiPar is now an independent, wholly owned subsidiary and center of innovation within the Sanofi-Aventis Group. He also serves on the Board of Directors at BayBio, Jennerex, SciDose, and on the Presidential Advisory Council of the Berklee College of Music. He was previously a member of the Board of Directors, Chief Operating Officer, and Head of the PEGylation Business Unit at Nektar Therapeutics (NASDAQ: NKTR). Dr. Huh was formerly a Partner at McKinsey and Company. Dr. Huh holds an M.D. from Cornell University Medical College, a Ph.D. in Genetics/Cell Biology from Cornell University/Sloan-Kettering Institute, and a bachelor's degree in biochemistry from Dartmouth College.
Oleg Nodelman, 34, U.S. citizen, is a Portfolio Manager at the Biotechnology Value Fund, a biotech focused investment fund founded in San Francisco in 1993. Before joining BVF, Mr. Nodelman was a consultant with Mercer Management Consulting where he worked closely with senior management on financial and strategic matters. Mr. Nodelman holds a Bachelor of Science in International Affairs and a minor in Science in Technology from the School of Foreign Service at Georgetown University. BVF is a 15.15% shareholder of Addex and on 14 March following conversion of outstanding notes will hold 30% of Addex.
Addex Pharmaceuticals (www.addexpharma.com) discovers and develops allosteric modulators for human health. The company uses its proprietary discovery platform to target cell surface receptors that are recognized as having therapeutic potential for treating diseases of the central nervous system, metabolic disorders or inflammation. Several Phase II clinical trials are expected to start soon for two lead products: dipraglurant (ADX48621) and ADX71149. Dipraglurant is an mGluR5 negative allosteric modulator (NAM), which will be tested in Parkinson's disease levodopa-induced dyskinesia (PD-LID) and, separately, non-Parkinsonian patients suffering from dystonia, a movement disorder also observed in PD. The PD-LID clinical trial is supported by a grant from The Michael J. Fox Foundation for Parkinson's Research. ADX71149 is an mGluR2 positive allosteric modulator (PAM), which has potential for treatment of schizophrenia, anxiety and other indications. ADX71149 is licensed to Ortho-McNeil-Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson. In addition, Merck & Co., Inc. has licensed rights to two preclinical programs: mGluR4 PAM for Parkinson's disease and mGluR5 PAM for schizophrenia. Unpartnered products in preclinical testing include: follicle stimulating hormone receptor (FSHR) NAM, with potential for endometriosis and benign prostatic hyperplasia; mGluR2 NAM for Alzheimer's disease; and GABA-B receptor PAM with potential for chronic pain, Fragile X syndrome, urinary incontinence and GERD. Preclinical diabetes and inflammation discovery programs include GLP1R PAM, IL1R1 NAM, and TNFR1 NAM.
Chris Maggos Business Development & Communication Addex Pharmaceuticals +41 22 884 15 11 chris.maggos(at)addexpharma.com
